Clinical Trials Logo

Mucopolysaccharidoses clinical trials

View clinical trials related to Mucopolysaccharidoses.

Filter by:

NCT ID: NCT00176891 Completed - Clinical trials for Mucopolysaccharidosis I

Stem Cell Transplant w/Laronidase for Hurler

Start date: March 2004
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that weekly infusions of Laronidase ERT for 10-12 weeks prior to transplant and 8 weeks following transplant will result in a reduction of glycosaminoglycans (GAG) burden that is associated with decreased complications following transplant.

NCT ID: NCT00146770 Completed - Clinical trials for Mucopolysaccharidosis I

Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

Start date: May 2001
Phase: Phase 3
Study type: Interventional

This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.

NCT ID: NCT00146757 Completed - Clinical trials for Mucopolysaccharidosis I

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

Start date: October 2002
Phase: Phase 2
Study type: Interventional

The main objectives of this study are to evaluate the safety and pharmacokinetics (PK) of enzyme replacement therapy with recombinant human alpha-L-iduronidase [Aldurazyme® (laronidase)] in mucopolysaccharidosis I (MPS I) patients less than 5 years old. Efficacy measurements will also be evaluated in this study.

NCT ID: NCT00144781 Completed - Clinical trials for Mucopolysaccharidosis I

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

Start date: December 2004
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).

NCT ID: NCT00144768 Completed - Clinical trials for Mucopolysaccharidosis I

A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.

NCT ID: NCT00104234 Completed - Clinical trials for Mucopolysaccharidosis VI

Study of rhASB in Patients With Mucopolysaccharidosis VI

Start date: February 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the long-term efficacy and safety of rhASB treatment in patients with Mucopolysaccharidosis VI.

NCT ID: NCT00069641 Completed - Clinical trials for Mucopolysaccharidosis II

Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Start date: September 18, 2003
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.

NCT ID: NCT00067470 Completed - Clinical trials for Mucopolysaccharidosis VI

Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients With MPS VI

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the ability of rhASB versus placebo to enhance endurance in patients with Mucopolysaccharidosis VI (MPS VI), as evidenced by an increase in the number of meters walked in the 12 minute walk test at Week 24 compared with baseline.

NCT ID: NCT00048711 Completed - Clinical trials for Mucopolysaccharidosis VI

Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI

Start date: March 2002
Phase: Phase 2
Study type: Interventional

The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)

NCT ID: NCT00048620 Completed - Clinical trials for Mucopolysaccharidosis VI

Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Start date: September 2000
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.